June 2014
FFMI team members will be at the BIO International Conference, June 23-26 in San Diego at the Michigan Pavilion Exhibit #537. Going? Contact Brad Martin at or 734-936-8577 to set up a meeting.
About 12,500 in Michigan to get surgery boot camp


Cheaper eye drug could save Medicare $18 billion


Phone app might predict manic episodes In bipolar disorder

The transformative power of transparency



U-M Medical School


UMMS Office of Research


Medicine at Michigan


U-M Business Engagement Center


U-M Tech Transfer


U-M Main Page 





Catch the Wave of the Digital Medicine Revolution

FREE July 9 Innovator Series Event

When it comes to digital health innovation, what's the best way to navigate early-stage prototyping and coding needs? What about customer discovery? Or the uncertain regulatory landscape?  Join our panel of experts as they discuss the trends, share experiences, and most importantly highlight U-M resources to help you join the Digital Healthcare Revolution!    

Wednesday, July 9
5:00pm Session 
6:00pm Networking Reception 
Research Auditorium, NCRC Building 10
  • Lawrence An, M.D., Associate Professor, Director of the Center for Health Communications Research, and Fast Forward Medical Innovation Champion   
  • Ulysses Balis, M.D., Professor and Fast Forward Medical Innovation Champion  
  • Drew Bennett, M.B.A., U-M Tech Transfer Senior Licensing Specialist, Software, Mobile and Digital Technologies 
  • David Morin, Founder, Mountain Pass Solutions
  • Nathan Hughes, Co-Founder, Detroit Labs

Part of the "Fast Forward Innovator Series 2014," this event is co-sponsored by Fast Forward Medical Innovation, the Medical School Office of Research, and U-M Tech Transfer.


CLICK HERE to register for this free event.  


New Partnership with NovoDynamics  

U-M's MCIRCC Working with Industry to Streamline Critical Care Diagnostics

In a move to impact both patient health and the critical care industry, the U-M Center for Integrative Research in Critical Care(MCIRCC) has announced a new partnership with NovoDynamics, Inc. - a company that develops pattern recognition and predictive analytics solutions - to advance the efficacy of critical illness and traumatic injury. 

When treating a critically ill or injured patient, physicians and clinicians are confronted with a multitude of time-related variables including, but not limited to, heart rate, blood pressure,
intracranial pressure, cerebral blood flow, brain tissue oxygenation, imaging scans, laboratory results, medical history and patient feedback. And yet, as humans we can only determine the relationship between two variables unassisted. Furthermore, all this health data is typically stored and analyzed as separate, unrelated resources.

Combined, these factors can lead to a delay in, or incomplete, diagnosis during the early stages of critical care and traumatic injury which directly impact patient treatment, outcomes and later, quality of life. To combat this information overload and enhance the situational awareness for critical care teams, MCIRCC has entered into a master collaboration agreement with NovoDynamics to accelerate the development and commercialization of the next generation of clinical decision support (CDS) solutions to improve patient outcomes, enhance the clinician experience and reduce healthcare costs.

Under the agreement, MCIRCC and NovoDynamics will develop real-time CDS solutions driven by adaptive learning algorithms operating on large datasets of patient information including medical images, real-time biosensor data, laboratory values, patient histories and treatment outcomes. Ultimately, the development and commercialization of these cutting-edge technologies will provide critical care physicians and clinicians better tools to quickly diagnose traumatic injuries for the implementation of personalized, time-sensitive treatments.

"This collaboration marries the strengths of MCIRCC/U-M's translational research, particularly critical care, predictive analytics, and signal processing, with NovoDynamics' expertise in advanced pattern recognition, image analysis, data mining and product commercialization," said Kevin R. Ward, M.D., executive director of MCIRCC, as well as U-M's Fast Forward Medical Innovation. "We are pleased to join forces with NovoDynamics to aggressively tackle critical care trauma and the burden it poses on the patient, clinician and healthcare system."

"Trauma is the leading cause of death for Americans between the ages of 1 and 44 and critical care represents a yearly cost to the economy in excess of $260 billion, that's nearly 40 percent of total hospital costs," said David A. Rock, president and chief executive officer at NovoDynamics.

This partnership is just the first of many collaborative ventures with industry who share MCIRCC's patient-focused mission and vision for delivering evidence-based "personalized" medicine across the spectrum of critical care.

Though there is currently no dollar value associated with this agreement and details will be worked out as the partnership evolves, if successful, the results will be invaluable to critical care support and patient quality of life. The idea is to go from "bench to bedside" and deliver real world solutions as quickly and efficiently as possible. 

Questions about other collaboration opportunities with NovoDynamics? Contact Stephanie Morley on the FFMI Business Development team via email or at 734-764-3635.  



FFMI Launches "i2i: Idea to Impact" Series

Events Supporting Research & Commercialization Offer CME Credit 

Breaking new ground in commercialization education here at the University, Fast Forward Medical Innovation (FFMI) recently announced its i2i: Idea to Impact series, sessions which have been approved for AMA PRA Category 1 credit through the U-M Office of Continuous Professional Development.
The next session, "The Secrets of Non-Disclosure Agreements" is scheduled for Wednesday, July 30 at 5:30 PM and will feature instructors Ed Pagani from U-M Tech Transfer and Anthony Nielsen from the U-M Office of Research and Sponsored Projects. More details about this class, as well as the other monthly sessions planned for the future, can be found at the FFMI Commercialization Education webpage.

"Educating faculty and staff about the multiple paths to successful commercialization is a key component of FFMI," noted Kevin Ward, M.D., Executive Director of FFMI. "i2i: Idea to Impact sessions will be a valuable educational opportunity for the novice and experienced innovator alike."

CME-approved educational sessions are just one of many ways that Fast Forward Medical Innovation is working to further deepen understanding of commercialization strategies, helping biomedical faculty at the University of Michigan develop a vision to translate research into an opportunity to impact.

To ensure that our educational programs meet the needs and busy schedules of biomedical faculty, we are asking that you take a short Needs Assessment Survey. By completing the Needs Assessment Survey, you're telling us exactly what you want to learn and how you want to learn it.

Please visit the FFMI Commercialization Education webpage for more information and instructions on how to take the survey.

Questions? Contact Jon Servoss, FFMI Commercialization Education Coordinator, via email or phone at 734-764-2692.  


MedImmune Collaboration Marks Year Two  

null Researchers from the U-M Medical School and MedImmune, the global biologics arm of AstraZeneca, recently participated in an update meeting at the company's headquarters in Gaithersburg, MD. This is the second year of a 3-year collaboration to work together on projects that aim to translate scientific discoveries from laboratory into new candidates for treating cancer and other diseases-specifically, cancer stem cells.

"It's year two of our relationship with MedImmune, and projects are progressing well," noted U-M Medical School Senior Associate Dean for Research and member of the joint steering committee Steven Kunkel, Ph.D. "Our investigators and MedImmune researchers are working closely and sharing their experiments and findings, and there are talks to move the projects to Phase 1 clinical trials."

A highlight of the meeting was a half-day mini symposium based on the science of the cancer stem cell projects. The symposium was well-attended by MedImmune researchers from other therapeutic areas and promoted the collaboration of U-M and MedImmune.


Questions about collaboration opportunities with MedImmune? Contact Debra Grega on the FFMI Business Development team via email or at 734-764-7815. 

About Us

The Fast Forward Medical Innovation team at the University of Michigan Medical School works to accelerate innovation and commercialization of research at its inception, collaborate with commercial partners via novel models, and enhance medical education by fostering innovation and entrepreneurship at all levels. We help UMMS faculty and strategic partners collaborate, with the ultimate goal of accelerating research and technology to improve human health. To connect, email us or call 734-615-5060.

Office of Research
Fast Forward Medical Innovation is part of the Office of Research, where our mission is to foster an environment of innovation and efficiency that serves the U-M Medical School community and supports biomedical science from insight to impact.